JP5200302B2 - ヘリカーゼを使用するrnaターゲットの同定 - Google Patents
ヘリカーゼを使用するrnaターゲットの同定 Download PDFInfo
- Publication number
- JP5200302B2 JP5200302B2 JP2007550481A JP2007550481A JP5200302B2 JP 5200302 B2 JP5200302 B2 JP 5200302B2 JP 2007550481 A JP2007550481 A JP 2007550481A JP 2007550481 A JP2007550481 A JP 2007550481A JP 5200302 B2 JP5200302 B2 JP 5200302B2
- Authority
- JP
- Japan
- Prior art keywords
- helicase
- rna
- amplification
- reaction
- hda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108060004795 Methyltransferase Proteins 0.000 title claims description 70
- 230000003321 amplification Effects 0.000 claims description 48
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 48
- 102100034343 Integrase Human genes 0.000 claims description 32
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 29
- 239000002299 complementary DNA Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 102000023732 binding proteins Human genes 0.000 claims description 11
- 108091008324 binding proteins Proteins 0.000 claims description 11
- 230000001419 dependent effect Effects 0.000 claims description 9
- 238000001502 gel electrophoresis Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000011901 isothermal amplification Methods 0.000 claims description 2
- 239000003155 DNA primer Substances 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 79
- 238000006243 chemical reaction Methods 0.000 description 64
- 239000000872 buffer Substances 0.000 description 31
- 238000010839 reverse transcription Methods 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 27
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 23
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 23
- 241000709661 Enterovirus Species 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000011543 agarose gel Substances 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 101710163270 Nuclease Proteins 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 7
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 101150112014 Gapdh gene Proteins 0.000 description 5
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000003161 ribonuclease inhibitor Substances 0.000 description 4
- 241000713838 Avian myeloblastosis virus Species 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000885581 Homo sapiens Frizzled-4 Proteins 0.000 description 2
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 2
- 238000007397 LAMP assay Methods 0.000 description 2
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000007039 two-step reaction Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010092681 DNA Primase Proteins 0.000 description 1
- 102000016559 DNA Primase Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
この実施例では、ヒト全RNAを核酸基質として使用し、最初にNew England Biolabs(New England Biolabs,Inc.,Ipswich,MA)製のProtoScriptRTMキットを使用して一本鎖cDNA産物に変換した。
1μlのヒト全RNA(1μg/μl)
2μlのプライマーdT23VN(50μM,New England Biolabs,Inc.,Ipswich,MA)
4μlのdNTP(2.5mM)
9μlのヌクレアーゼ非含有H2O
を混合して反応物を準備し、最初に70℃で5分間インキュベートし、次いで氷上に維持した。
2μlの10×RTバッファ(New England Biolabs,Inc.,Ipswich,MA)
1μlのRNaseインヒビター(10単位/μl)
1μlのM−MuLV逆転写酵素(25単位/μl)。
2.5μlの10×Mg非含有tHDAバッファ(下記参照*)
5μlの系列希釈RT産物(0.0001%−1%のRT産物)
0.5μlの10μMのプライマーGAPDF1(配列:1)
0.5μlの10μMのプライマーGAPDR1(配列:2)
16.5μlのdH2O。
2.5μlの10×Mg非含有tHDAバッファ(下記参照*)
1.75μlの100mMのMgSO4
2μlの500mMのNaCl
2μlの10mMのdNTP
1.5μlの100mMのdATP
2.5μlのBst DNAポリメラーゼ,LF(8単位/μl;New England Biolabs,Inc.,Ipswich,MA)
1μlのTte−UvrDヘリカーゼ(100ng/μl)
11.75μlのdH2O。
*10×Mg非含有tHDAバッファは100mMのKCl、100mMの(NH4)2SO4、200mMのトリス−HCl(25℃でpH8.8)、1%のTriton X−100を含有している。
この実施例では、第一鎖cDNA合成とtHDA反応とを合わせて1つの管で2段階インキュベーションを使用して行った。10pg−100ngの範囲の種々の量のヒト全RNAとGAPDH遺伝子の一対の特異的プライマーGAPDF1とGAPDR1とを増幅に使用した。
5μlの10×Mg非含有tHDAバッファ
1μlの可変量のヒト全RNA(10pg−100ng)
0.5μlの10μMプライマーGAPDF1(配列:1)
0.5μlの10μMプライマーGAPDR1(配列:2)
1.75μlの100mMのMgSO4
2μlの500mMのNaCl
2μlの10mMのdNTP
1.5μlの100mMのdATP
1μlのRNaseインヒビター(10単位/μl)
1μlのM−MuIV逆転写酵素(25単位/μl)
2.5μlのBst DNAポリメラーゼ,LF(8単位/μl,New England Biolabs,Inc.,Ipswich,MA)
1μlのTte−UvrDヘリカーゼ(100ng/μl)
30.25μlのヌクレアーゼ非含有H2O。
この実施例では、高い熱安定性をもつ逆転写酵素を選択し、第一鎖cDNA合成とヘリカーゼ依存性等温DNA増幅反応とを合わせて1つの管で1段階で行った。100pg−100ngの範囲の種々の量のヒト全RNAとGAPDH遺伝子の一対の特異的プライマーGAPDF1とGAPDR1とを増幅に使用した。
5μlのMg非含有tHDAバッファ
1μlの可変量のヒト全RNA(100pg−100ng)
0.5μlの10μMのプライマーGAPDF1(配列:1)
0.5μlの10μMのプライマーGAPDR1(配列:2)
1.75μlの100mMのMgSO4
2μlの500mMのNaCl
2μlの10mMのdNTP
1.5μlの100mMのdATP
1μlのSuperscriptTM III逆転写酵素(200単位/μl,Invitrogen,Carlsbad,CA)
2.5μlのBst DNAポリメラーゼ,LF(8単位/μl,New England Biolabs,Inc.,Ipswich,MA)
1μlのTte−UvrDヘリカーゼ(100ng/μl)
31.25μlのヌクレアーゼ非含有H2O。
この実施例では、非特異的増幅を低減するためにRNA鋳型およびプライマーの変性に関与する独立の変性段階を使用した。65℃で高い熱安定性をもつ逆転写酵素を選択し、第一鎖cDNA合成およびヘリカーゼ依存性等温DNA増幅反応を合わせて1つの管で1段階で行った。2pg−200ngの範囲の種々の量のヒト全RNAとGAPDH遺伝子の異なるエキソンに局在した一対の特異的プライマーGAPDF3とGAPDR3とを増幅に使用した。
2.5μlの10×RT−HDAバッファ(下記参照*)
2μlの可変量のヒト全RNA(2pg−200ng)
0.375μlの10μMのプライマーGAPDF3(配列:3)
0.375μlの10μMのプライマーGAPDR3(配列:4)
19.75μlのヌクレアーゼ非含有H2O
全量:25μl。
2.5μlの10×RT−HDAバッファ(下記参照*)
1.75μlの100mMのMgSO4
4μlの500mMのNaCl
2μlの10mMのdNTP
1.5μlの100mMのdATP
0.5μlのRNaseインヒビター(40単位/μl,New England Biolabs,Inc.,Ipswich,MA)
0.7μlのThermoScript逆転写酵素(15単位/μl,Invitrogen)
2.5μlのBst DNAポリメラーゼ,LF(8単位/μl,New England Biolabs,Inc.,Ipswich,MA)
1μlのTte−UvrDヘリカーゼ(150ng/μl)
8.55μlのヌクレアーゼ非含有H2O
全量:25μl。
*10×RT−HDAバッファは、100mMのKCl、200mMのトリス−HCl(25℃でpH8.8)を含有している。
この実施例では、実施例4に記載した修正1段階RT−HDA法をRNAウイルスであるエンテロウイルスの検出に応用した。エンテロウイルスClear QCパネル(Argene,Varilhes,France)から精製した40コピーから4000コピーの範囲のエンテロウイルスRNAを鋳型として使用し、エンテロウイルスの全種に保存された5’−UTR配列をターゲットとする一対の特異的プライマーEVF1AおよびEVR1を増幅用プライマーとして使用した。
2.5μlの10×RT−HDAバッファ(下記参照*)
2μlの可変量のエンテロウイルスRNA(40−4000コピー)
0.375μlの10μMのプライマーEVF1A(配列:5)
0.375μlの10μMのプライマーEVR1(配列:6)
19.7μlのヌクレアーゼ非含有H2O
全量:25μl。
2.5μlの10×RT−HDAバッファ(下記参照*)
1.75μlの100mMのMgSO4
2μlの500mMのNaCl
2μlの10mMのdNTP
1.5μlの100mMのdATP
0.5μlのRNaseインヒビター(40単位/μl,New England Biolabs,Inc.,Ipswich,MA)
0.7μlのThermoScript逆転写酵素(15単位/μl,Invitrogen)
2.5μlのBst DNAポリメラーゼ,LF(8単位/μl,New England Biolabs,Inc.,Ipswich,MA)
1μlのTte−UvrDヘリカーゼ(150ng/μl)
10.55μlのヌクレアーゼ非含有H2O
全量:25μl。
*10×RT−HDAバッファは、100mMのKCl、200mMのトリス−HCl(25℃でpH8.8)を含有している。
Claims (6)
- RNAのヘリカーゼ依存性増幅方法であって、
(a)RNAに、逆転写酵素と、ヘリカーゼと、該ヘリカーゼが熱安定ヘリカーゼでない場合一本鎖結合タンパク質と(前記ヘリカーゼが熱安定ヘリカーゼである場合、前記一本鎖結合タンパク質を要さない)、複数のオリゴヌクレオチドプライマーと、1つ又は複数のポリメラーゼとを含む混合物を添加する段階、
(b)混合物中で、RNAを逆転写して、cDNAを形成し、ヘリカーゼ依存性増幅によって該cDNAを増幅させる段階であって、ここで、ゲル電気泳動によって決定されるように、ヘリカーゼの非存在下では増幅が起こらない、段階
を含む方法。 - ヘリカーゼの調製物がUvrDヘリカーゼを含む請求項1に記載の方法。
- UvrDヘリカーゼが熱安定ヘリカーゼである請求項2に記載の方法。
- ヘリカーゼ依存性増幅が等温的である請求項1に記載の方法。
- 等温増幅が20℃〜75℃の範囲内の温度で生じる請求項4に記載の方法。
- ポリメラーゼがBstポリメラーゼである請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64141905P | 2005-01-05 | 2005-01-05 | |
US60/641,419 | 2005-01-05 | ||
PCT/US2006/000406 WO2006074334A2 (en) | 2005-01-05 | 2006-01-05 | Identification of rna targets using helicases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008526231A JP2008526231A (ja) | 2008-07-24 |
JP5200302B2 true JP5200302B2 (ja) | 2013-06-05 |
Family
ID=36648189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007550481A Active JP5200302B2 (ja) | 2005-01-05 | 2006-01-05 | ヘリカーゼを使用するrnaターゲットの同定 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1833995B1 (ja) |
JP (1) | JP5200302B2 (ja) |
DK (1) | DK1833995T3 (ja) |
ES (1) | ES2643718T3 (ja) |
SI (1) | SI1833995T1 (ja) |
WO (1) | WO2006074334A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2140033B1 (en) | 2007-03-28 | 2012-10-10 | Signal Diagnostics | System and method for high resolution analysis of nucleic acids to detect sequence variations |
US10669574B2 (en) | 2008-11-18 | 2020-06-02 | XCR Diagnostics, Inc. | DNA amplification technology |
JP2012516155A (ja) * | 2009-01-27 | 2012-07-19 | キアゲン ゲーザーズバーグ | エンドポイント均一蛍光検出を用いた好熱性ヘリカーゼ依存性増幅技術 |
CN102791884A (zh) * | 2010-01-08 | 2012-11-21 | 奇亚根盖瑟斯堡股份有限公司 | 用于等温核酸扩增的材料和方法 |
EP2420579A1 (en) | 2010-08-17 | 2012-02-22 | QIAGEN GmbH | Helicase dependent isothermal amplification using nicking enzymes |
CN102827949B (zh) * | 2012-08-16 | 2014-07-23 | 浙江省疾病预防控制中心 | 一种麻疹病毒RT-tHDA检测试剂盒及检测方法 |
WO2014210416A1 (en) * | 2013-06-27 | 2014-12-31 | New England Biolabs, Inc. | Helicase suppression of non-template amplification |
US10370707B2 (en) | 2013-10-09 | 2019-08-06 | Fluoresentric, Inc. | Multiplex probes |
JP6967214B2 (ja) * | 2015-11-27 | 2021-11-17 | 国立大学法人京都大学 | 新規核酸合成法 |
JP6448695B2 (ja) * | 2017-03-21 | 2019-01-09 | 株式会社東芝 | Rna増幅方法、rna検出方法及びアッセイキット |
CN116497102A (zh) * | 2021-12-21 | 2023-07-28 | 成都齐碳科技有限公司 | 用于表征目标多核苷酸的衔接体、方法及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194370A (en) * | 1990-05-16 | 1993-03-16 | Life Technologies, Inc. | Promoter ligation activated transcription amplification of nucleic acid sequences |
WO1993014217A1 (en) * | 1992-01-10 | 1993-07-22 | Life Technologies, Inc. | Use of predetermined nucleotides having altered base pairing characteristics in the amplification of nucleic acid molecules |
AU2003272438B2 (en) * | 2002-09-20 | 2009-04-02 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
DE10314745A1 (de) * | 2003-03-31 | 2004-10-14 | Ignatov, Konstantin | Zyklische Nukleinsäure-Amplifikation mittels einer Helicase |
US20050069926A1 (en) * | 2003-08-01 | 2005-03-31 | Affymetrix, Inc. | Helicase-amplified reverse transcription |
-
2006
- 2006-01-05 ES ES06717583.6T patent/ES2643718T3/es active Active
- 2006-01-05 DK DK06717583.6T patent/DK1833995T3/en active
- 2006-01-05 JP JP2007550481A patent/JP5200302B2/ja active Active
- 2006-01-05 SI SI200632205T patent/SI1833995T1/sl unknown
- 2006-01-05 EP EP06717583.6A patent/EP1833995B1/en active Active
- 2006-01-05 WO PCT/US2006/000406 patent/WO2006074334A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2006074334A3 (en) | 2007-01-04 |
EP1833995B1 (en) | 2017-08-02 |
WO2006074334A2 (en) | 2006-07-13 |
EP1833995A2 (en) | 2007-09-19 |
SI1833995T1 (sl) | 2017-10-30 |
JP2008526231A (ja) | 2008-07-24 |
DK1833995T3 (en) | 2017-10-02 |
ES2643718T3 (es) | 2017-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5200302B2 (ja) | ヘリカーゼを使用するrnaターゲットの同定 | |
US20230099446A1 (en) | Fast pcr for str genotyping | |
Goldmeyer et al. | Development of a novel one-tube isothermal reverse transcription thermophilic helicase-dependent amplification platform for rapid RNA detection | |
JP6966681B2 (ja) | 限られたヌクレオチド組成を有するプライマーを用いた増幅 | |
JP5945271B2 (ja) | ニッキング酵素を用いたヘリカーゼ依存性等温増幅 | |
US10301675B2 (en) | Compositions and methods for reducing inhibition of RT-PCR | |
JP5680080B2 (ja) | アンカーオリゴヌクレオチドおよびアダプターオリゴヌクレオチドを用いる核酸の正規化した定量化方法 | |
US10793896B2 (en) | Methods for RT-PCR comprising an anionic polymer | |
JP5680078B2 (ja) | ライゲーションに基づく核酸の正規化した定量化方法 | |
JP2014506794A (ja) | 内部コントロールを使用するヒトdnaを定量するための方法 | |
CN109097450B (zh) | 一种核酸序列非依赖的全rna扩增方法 | |
WO2023073143A1 (en) | Nucleic acid amplification method | |
US20140162276A1 (en) | Method of amplifying target nucleic acid, method of analyzing target nucleic acid, kit for amplifying target nucleic acid, and composition for amplifying target nucleic acid | |
JP2009000035A (ja) | 長塩基核酸増幅法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110804 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110811 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130108 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130125 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130125 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5200302 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160222 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |